Ecopia BioSciences Inc.

Ecopia BioSciences Inc.

November 08, 2006 16:30 ET

Ecopia to Present at the EORTC-NCI-AACR Meeting in Prague

MONTREAL, QUEBEC--(CCNMatthews - Nov. 8, 2006) - Ecopia BioSciences Inc. (TSX:EIA) is pleased to announce it will present two scientific posters at the 18th EORTC-NCI-AACR Meeting, held in Prague. The data presented support the unique mechanism of action of ECO-4601 as well as its strong safety profile. ECO-4601, the Company's lead anticancer drug candidate now in a Phase I clinical trial, has a dual mechanism of action. Not only does the compound inhibit the RAS-mitogen-activated protein kinase (MAPK) pathway at a strategic point, it also selectively binds to the Peripheral Benzodiazepine Receptor (PBR), a receptor highly expressed in many cancer cells. This dual activity positions the compound as a uniquely targeted anticancer drug candidate that is now being tested in a Phase I clinical trial involving patients with refractory solid tumors, including pancreatic cancer and glioblastoma.

The first poster, presented by Dr. Henriette Gourdeau, Associate Director, Pharmacology and Toxicology, is entitled: The anticancer agent, ECO-4601, is a potent inhibitor of the Ras-mitogen activated protein kinase pathway. The data describe supporting evidence that ECO-4601 inhibits the MAPK pathway, an important target pathway for anticancer therapies. Furthermore, a second poster, entitled Safety profile in primates of the anticancer agent ECO-4601, a novel PBR ligand and Ras signaling inhibitor, reveals preclinical safety data collected following the administration of ECO-4601 to cynomolgus monkeys. Results showed no toxicity at drug plasma levels above expected target drug concentrations to be achieved in humans. An adequate margin of safety for ECO-4601 was established under clinically relevant dosing conditions in the monkeys and supported advancement into current and future clinical trials.

Both posters will be available on Ecopia's website as of November 10, 2006.

About Ecopia

Ecopia is finding novel anticancer therapies using its proprietary platform DECIPHER® technology. The Company's current focus is to move its lead compound, ECO-4601, through the early clinical phases. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting tumor growth in several xenograft models. It acts through a dual action by blocking the RAS pathway as well as by binding to the Peripheral Benzodiazepine Receptor (PBR), a receptor highly expressed in many cancer cells. ECO-4601 represents a new chemical class owned by Ecopia that is now in a Phase l clinical trial. The novel scaffold of this molecule is the basis for multiple lead compounds at the preclinical stage.

The common shares of Ecopia are listed on the TSX (symbol: EIA).

Additional information about the Company can be obtained from Ecopia's website at

This press release contains forward-looking statements and should be read in conjunction with the discussion on risks and uncertainties disclosed in the Company's press release dated October 10, 2006 regarding operating highlights and financial results for the third quarter of fiscal year 2006, and the 2005 annual information form, both of which are available on

Contact Information